GENOMIC EDITING OF GENES INVOLVED IN CARDIOVASCULAR DISEASE
The present invention provides genetically modified animals and cells comprising edited chromosomal involved in cardiovascular disease. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequences involved in cardiovascular disease and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.
1 . A genetically modified animal comprising at least one edited chromosomal sequence encoding a protein involved in cardiovascular disease.
2 . The genetically modified animal of claim 1 , wherein the edited chromosomal sequence is inactivated, modified, or comprises an integrated sequence.
3 . The genetically modified animal of claim 1 , wherein the edited chromosomal sequence is inactivated such that no functional cardiovascular-related protein is produced.
4 . The genetically modified animal of claim 3 , wherein the inactivated chromosomal sequence comprises no exogenously introduced sequence.
5 . The genetically modified animal of claim 3 , further comprising at least one chromosomally integrated sequence encoding a functional protein involved in cardiovascular disease.
6 . The genetically modified animal of 4, wherein the chromosomal sequence encoding a protein involved in cardiovascular disease is chosen from Cacna1C, Sod1, Pten, Ppar(alpha), ApoE, Leptin, and combinations thereof.
7 . The genetically modified animal of claim 1 , further comprising a conditional knock-out system for conditional expression of the cardiovascular disease-related protein.
8 . The genetically modified animal of claim 1 , wherein the edited chromosomal sequence comprises an integrated reporter sequence.
9 . The genetically modified animal of claim 1 , wherein the animal is heterozygous or homozygous for at least one edited chromosomal sequence.
10 . The genetically modified animal of claim 1 , wherein the animal is an embryo, a juvenile, or an adult.
11 . The genetically modified animal of claim 1 , wherein the animal is chosen from a bovine, canine, equine, feline, ovine, porcine, non-human primate, and rodent.
12 . The genetically modified animal of claim 1 , wherein the animal is rat.
13 . The genetically modified animal of claim 1 , wherein the animal is rat and the othologous protein involved in cardiovascular disease is human.
14 . A non-human embryo, the embryo comprising at least one RNA molecule encoding a zinc finger nuclease that recognizes a chromosomal sequence involved in cardiovascular disease, and, optionally, at least one donor polynucleotide comprising a sequence encoding a protein encoded by the chromosomal sequence involved in cardiovascular disease.
15 . The non-human embryo of 14, wherein the protein encoded by the chromosomal sequence involved in cardiovascular disease is chosen from Cacna1C, Sod1, Pten, Ppar (alpha), ApoE, Leptin, and combinations thereof.
16 . The non-human embryo of claim 14 , wherein the embryo is chosen from bovine, canine, equine, feline, ovine, porcine, primate, or rodent.
17 . The non-human embryo of claim 14 , wherein the embryo is a rat and the protein is an orthologous protein encoded by a chromosomal sequence involved in cardiovascular disease is human.
18 . A genetically modified cell, the cell comprising at least one edited chromosomal sequence involved in cardiovascular disease.
19 . The genetically modified cell of claim 18 , wherein the edited chromosomal sequence is inactivated, modified, or comprises an integrated sequence.
20 . The genetically modified cell of claim 18 , wherein the edited chromosomal sequence is inactivated such that no functional cardiovascular-related protein is produced.
21 . The genetically modified cell of claim 20 , wherein the inactivated chromosomal sequence comprises no exogenously introduced sequence.
22 . The genetically modified cell of claim 21 , further comprising at least one chromosomally integrated sequence encoding a functional protein involved in cardiovascular disease.
23 . The genetically modified cell 18, wherein the protein encoded by the chromosomal sequence involved in cardiovascular disease is chosen from Cacna1C, Sod1, Pten, Ppar(alpha) Apo E, Leptin, and combinations thereof.
24 . The genetically modified cell of claim 18 , further comprising a conditional knock-out system for conditional expression of the cardiovascular disease-related protein.
25 . The genetically modified cell of claim 18 , wherein the edited chromosomal sequence comprises an integrated reporter sequence.
26 . The genetically modified cell of claim 18 , wherein the cell is heterozygous or homozygous for the at least one edited chromosomal sequence.
27 . The genetically modified cell of claim 18 , wherein the cell is chosen from bovine, canine, equine, feline, human, ovine, porcine, non-human primate, and rodent origin.
28 . The genetically modified cell of claim 18 , wherein the cell is of rat origin and the orthologous protein encoded by a chromosomal sequence involved in cardiovascular disease is human.
29 . A zinc finger nuclease, the zinc finger nuclease comprising:
a) a zinc finger DNA binding domain that binds a sequence having at least about 80% sequence identity with a sequence chosen from SEQ ID NOs:4, 5, 6 and 7.
b) a cleavage domain.
30 . The zinc finger nuclease of claim 29 , wherein the sequence identity is at least about 85%, 90%, 95%, or 100%.
31 . The zinc finger nuclease of claim 29 , wherein the DNA binding domain comprises at least 3 zinc finger recognition regions.
32 . The zinc finger nuclease of claim 29 , wherein the cleavage domain is a wild-type or an engineered FokI cleavage domain.
33 . A nucleic acid encoding the zinc finger nuclease of claim 29 .
34 . A nucleic acid sequence bound by a zinc finger nuclease, the nucleic acid sequence having at least about 80% sequence identity with a sequence chosen from SEQ ID NOs: 4, 5, 6 and 7.
35 . A method for assessing the effect of an agent in an animal, the method comprising contacting a genetically modified animal, comprising at least one edited chromosomal sequence encoding a protein involved in cardiovascular disease, with the agent and comparing results of a selected parameter to results obtained from contacting a wild-type animal with the same agent, wherein the selected parameter is chosen from:
a) rate of elimination of the agent or its metabolite(s);
b) circulatory levels of the agent or its metabolite(s);
c) bioavailability of the agent or its metabolite(s);
d) rate of metabolism of the agent or its metabolite(s);
e) rate of clearance of the agent or its metabolite(s);
f) toxicity of the agent or its metabolite(s); and
g) efficacy of the agent or its metabolite(s).
36 . The method of claim 35 , wherein the agent is a pharmaceutically active ingredient, a drug, a toxin, or a chemical.
37 . The method of claim 35 , wherein the at least one edited chromosomal sequence is inactivated such that the protein involved in cardiovascular disease is not produced or is not functional, and wherein the animal further comprises at least one chromosomally integrated sequence encoding an ortholog of the protein involved in cardiovascular disease.
38 . The method of claim 35 , wherein the protein involved in cardiovascular disease is chosen from Cacna1C, Sod1, Pten, Ppar(alpha), Apo E, Leptin, and combinations thereof.